TY - JOUR
T1 - Evaluating Antiangiogenesis Agents in the Clinic
T2 - The Eastern Cooperative Oncology Group Portfolio of Clinical Trials
AU - Sparano, Joseph A.
AU - Gray, Robert
AU - Giantonio, Bruce
AU - O'Dwyer, Peter
AU - Comis, Robert L.
PY - 2004/2/15
Y1 - 2004/2/15
N2 - Recent evidence indicates that treatment with a humanized monoclonal antibody (bevacizumab) directed at vascular endothelial growth factor improves response and survival in metastatic colorectal cancer when added to standard chemotherapy, validating angiogenesis as a therapeutic target. Investigators from the Eastern Cooperative Oncology Group (ECOG) have initiated a number of Phase III studies that will help further define the role of antiangiogenic agents for the treatment of breast, colon, lung, renal, and head and neck cancer, as well as melanoma and myeloma. The agents being evaluated target various biological functions involved in angiogenesis, including vascular endothelial growth factor (bevacizumab), endothelial cell proliferation (thalidomide, IFN-α), and matrix metalloproteinases (marimastat). These clinical trials include correlative laboratory studies aimed at elucidating how these agents may exert their clinical effects. The portfolio of Eastern Cooperative Oncology Group studies will serve to further define the role of this therapeutic strategy for patients with advanced cancer.
AB - Recent evidence indicates that treatment with a humanized monoclonal antibody (bevacizumab) directed at vascular endothelial growth factor improves response and survival in metastatic colorectal cancer when added to standard chemotherapy, validating angiogenesis as a therapeutic target. Investigators from the Eastern Cooperative Oncology Group (ECOG) have initiated a number of Phase III studies that will help further define the role of antiangiogenic agents for the treatment of breast, colon, lung, renal, and head and neck cancer, as well as melanoma and myeloma. The agents being evaluated target various biological functions involved in angiogenesis, including vascular endothelial growth factor (bevacizumab), endothelial cell proliferation (thalidomide, IFN-α), and matrix metalloproteinases (marimastat). These clinical trials include correlative laboratory studies aimed at elucidating how these agents may exert their clinical effects. The portfolio of Eastern Cooperative Oncology Group studies will serve to further define the role of this therapeutic strategy for patients with advanced cancer.
UR - http://www.scopus.com/inward/record.url?scp=1642321097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642321097&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-03-0238
DO - 10.1158/1078-0432.CCR-03-0238
M3 - Review article
C2 - 14977816
AN - SCOPUS:1642321097
SN - 1078-0432
VL - 10
SP - 1206
EP - 1211
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -